Cantor Fitzgerald Expects Weaker Earnings for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Cabaletta Bio in a research note issued on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($1.38) for the year, down from their previous forecast of ($1.22). The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 21st. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.04).

Other equities analysts also recently issued reports about the stock. Guggenheim boosted their target price on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price on shares of Cabaletta Bio in a report on Tuesday, April 1st. Citigroup lowered their price target on Cabaletta Bio from $17.00 to $13.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. UBS Group reduced their target price on Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Morgan Stanley reduced their price objective on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a research report on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $20.33.

Cabaletta Bio Stock Down 2.1%

Shares of Cabaletta Bio stock opened at $1.88 on Wednesday. The stock has a market cap of $95.40 million, a P/E ratio of -0.87 and a beta of 2.72. Cabaletta Bio has a 12-month low of $0.99 and a 12-month high of $13.50. The business's 50 day moving average is $1.37 and its 200-day moving average is $2.19.

Institutional Investors Weigh In On Cabaletta Bio

Institutional investors and hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. increased its stake in Cabaletta Bio by 10.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,074,006 shares of the company's stock valued at $9,248,000 after acquiring an additional 400,282 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Cabaletta Bio by 19.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,634,473 shares of the company's stock worth $8,250,000 after acquiring an additional 597,828 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Cabaletta Bio by 89.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company's stock valued at $2,874,000 after purchasing an additional 598,607 shares during the last quarter. Geode Capital Management LLC lifted its stake in Cabaletta Bio by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,110,702 shares of the company's stock valued at $2,522,000 after purchasing an additional 16,058 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its position in Cabaletta Bio by 195.8% in the fourth quarter. Two Sigma Advisers LP now owns 831,900 shares of the company's stock valued at $1,888,000 after buying an additional 550,700 shares in the last quarter.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.